Rybelsus quick facts
| Active ingredient | Semaglutide, the same molecule as Ozempic and Wegovy |
| Drug class | GLP-1 receptor agonist |
| Maker | Novo Nordisk |
| How taken | Once-daily tablet, on an empty stomach with no more than 4 oz of water |
| FDA-approved use | Type 2 diabetes. Not approved for weight management |
| Doses | 3, 7 and 14 mg daily |
| Status | All three strengths marked "To Be Discontinued" as of 4 June 2026 |
| Replaced by | Ozempic tablets, at 1.5, 4 and 9 mg |
Rybelsus is being discontinued
This is the fact that matters most about Rybelsus in 2026, and it is not yet reflected in most of what you will read about it.
The FDA's drug shortages database lists all three strengths — 3 mg, 7 mg and 14 mg — with the status To Be Discontinued, updated 4 June 2026. The reason given is discontinuation of the manufacture of the drug, and the database states plainly what happens next: "These products will be replaced by Ozempic (semaglutide) tablets."
Two things follow that are worth being clear about.
This is not a shortage. A shortage is a supply problem that resolves. A discontinuation is the product ending. Nothing is coming back into stock.
It is not a safety withdrawal either. Nothing about Rybelsus was found unsafe. Novo Nordisk is consolidating oral semaglutide under the Ozempic name, and the molecule you are taking continues to exist in a tablet with a different label on the box.
The clearest evidence of that consolidation is administrative: Rybelsus and Ozempic tablets now share a single label in DailyMed — one document covering both products, SPL version 13, published 20 May 2026. Regulators do not usually file two competing products on one label. They file a product and its successor.
What you switch to, and at what dose
The replacement is Ozempic tablets, and the doses do not carry across. Rybelsus runs 3, 7 and 14 mg; Ozempic tablets run 1.5, 4 and 9 mg.
| Rybelsus dose | Ozempic tablet dose |
|---|---|
| 3 mg | 1.5 mg |
| 7 mg | 4 mg |
| 14 mg | 9 mg |
The smaller number is not a smaller dose. The two products use different formulations, and the label sets these as the equivalent steps rather than as a reduction. Somebody moving from 14 mg to 9 mg has not been cut back by a third, and a pharmacist or prescriber who says otherwise has misread the conversion.
The full detail, including how titration works across the switch, is in the Rybelsus to Ozempic conversion guide.
How Rybelsus works
Rybelsus is semaglutide — the identical molecule to Ozempic and Wegovy — delivered as a tablet rather than an injection. Peptides are normally destroyed by stomach acid, which is why almost every GLP-1 is injected. Rybelsus gets around that with an absorption enhancer called SNAC, which raises the local pH in the stomach long enough for some of the semaglutide to cross into the bloodstream.
"Some" is doing real work in that sentence. Oral bioavailability is low and variable, which is why the tablet doses look large next to the injection: 14 mg daily by mouth against 2 mg weekly by injection. It is also why the administration rules are unusually strict.
The empty-stomach rule, and why it is not optional
Rybelsus has to be taken on waking, on an empty stomach, with no more than four ounces of plain water — and nothing else to eat or drink for at least 30 minutes afterwards.
This is not a general "take with water" instruction. Food, coffee and even a larger volume of water reduce absorption substantially, and someone taking the tablet with breakfast may be getting a fraction of the dose. It is the most common reason a person reports that Rybelsus "did nothing" for them.
The same rule applies to Ozempic tablets after the switch, so it is not a habit anyone gets to drop.
What results to expect
Rybelsus is approved for type 2 diabetes only, not for weight management, and the distinction matters both clinically and for coverage.
Weight loss on Rybelsus is real but modest — in the region of 3 to 4% of body weight, against roughly 15% for semaglutide at the weight-management dose in Wegovy. Anyone taking it primarily to lose weight is using a diabetes product off-label at a dose never designed for that purpose, and is likely to be disappointed. See Rybelsus for weight loss.
If weight is the goal, the products designed for it are Wegovy — now available as an injection and a tablet — and Zepbound. See Rybelsus versus Wegovy and the Wegovy pill.
Side effects
The side-effect profile is the GLP-1 class profile: nausea, diarrhoea, vomiting, constipation and abdominal pain, worst during dose escalation and easing for most people over the following weeks. Oral semaglutide is not gentler than the injection simply for being a tablet.
The serious warnings are also the class warnings — pancreatitis, gallbladder disease, and the boxed warning about thyroid C-cell tumours seen in rodents. Our side-effect timeline sets out what tends to appear when.
Cost, and what changes when the product does
Rybelsus has carried a list price broadly in line with other Novo semaglutide products, and coverage has always depended on a type 2 diabetes diagnosis rather than on weight.
The switch changes the practical picture. Novo now sells oral semaglutide direct through NovoCare Pharmacy under the Ozempic name, with the tablet starting at $149 a month and pricing varying by dose — a self-pay route that did not exist for Rybelsus in the same form. Anyone being moved across should check what their plan does with the new product rather than assuming the old arrangement carries over. See our GLP-1 cost index and Medicare coverage.
What to do if you are taking Rybelsus now
- Do not stop. A discontinuation notice is not an instruction to come off the medication, and stopping a diabetes drug without a plan is the risk here, not the switch.
- Raise it at your next appointment rather than waiting for the pharmacy to raise it. The conversion is on the label and your prescriber can write the equivalent Ozempic tablet dose directly.
- Check the dose on the new box against the table above. A smaller number is expected and correct.
- Re-check coverage. A plan that covered Rybelsus is not guaranteed to have added Ozempic tablets to its formulary yet, and prior authorization may need redoing.
- Keep the empty-stomach routine. It transfers to the new product unchanged.
This article is educational and is not medical advice. Discontinuation status, dosing and coverage change; the FDA shortages entries above were re-verified on 10 August 2026. Do not stop or change a diabetes medication without speaking to your prescriber.
Scientific References
2 sources- 1
U.S. Food and Drug Administration
Drug Shortages — Semaglutide Tablet (Rybelsus 3 mg, 7 mg, 14 mg), status To Be Discontinued, updated 4 June 2026
U.S. Food and Drug Administration · 2026
- 2
Novo Nordisk
OZEMPIC (oral semaglutide) tablet / RYBELSUS (oral semaglutide) tablet — FDA prescribing information, SPL version 13
DailyMed, U.S. National Library of Medicine · 2026
NIH
References open in a new tab. Content is reviewed against peer-reviewed literature as part of our editorial policy.
About the author
Editor, Modern Weight Science
Claudiu Gheorghe is the editor of Modern Weight Science. He is not a physician. His role is to synthesize peer-reviewed studies, clinical-trial data, and FDA prescribing information into clear, plain-language explanations, and to make sure every factual claim on the site traces back to a cited source. Any decision about starting, changing, or stopping a medication belongs with a licensed clinician who knows your history.
Every claim is checked against peer-reviewed research through our review process and fact-checking policy.
Frequently Asked Questions
Is Rybelsus being discontinued?
Yes. The FDA's drug shortages database lists all three strengths — 3 mg, 7 mg and 14 mg — as “To Be Discontinued” as of 4 June 2026, with the reason given as discontinuation of manufacture and the note that the products will be replaced by Ozempic (semaglutide) tablets. This is not a shortage that resolves, and it is not a safety withdrawal.
What replaces Rybelsus?
Ozempic tablets, at 1.5, 4 and 9 mg. The two products now share a single DailyMed label — one document covering both, SPL version 13, published 20 May 2026 — which is the clearest administrative sign that Novo Nordisk is consolidating oral semaglutide under the Ozempic name.
What dose of Ozempic tablets replaces my Rybelsus dose?
The label conversions are 3 mg to 1.5 mg, 7 mg to 4 mg and 14 mg to 9 mg. The smaller number is not a smaller dose — the two products use different formulations, and these are the equivalent steps rather than a reduction.
Should I stop taking Rybelsus?
No. A discontinuation notice is not an instruction to stop, and stopping a type 2 diabetes medication without a plan is the real risk. Raise it at your next appointment rather than waiting for the pharmacy to raise it; your prescriber can write the equivalent Ozempic tablet dose directly from the label.
How much weight can you lose on Rybelsus?
Around 3 to 4% of body weight, which is modest against the roughly 15% seen with semaglutide at the weight-management doses used in Wegovy. Rybelsus is approved for type 2 diabetes only, so taking it for weight is off-label use of a product at doses never designed for that purpose.
Why does Rybelsus have to be taken on an empty stomach?
Oral semaglutide is absorbed poorly and variably, and food, coffee or more than about four ounces of water cut absorption substantially. The tablet must be taken on waking with no more than four ounces of plain water and nothing else for at least 30 minutes. Taking it with breakfast is the most common reason someone reports that it did nothing, and the same rule carries over to Ozempic tablets.
Continue learning
Where to read next
Not medical advice. This guide is for general education only. GLP-1 medications, dosing, and treatment suitability are decisions for you and a licensed clinician who knows your full medical history.